Targeted therapy for psoriasis: Pathogenetic aspects and effectiveness

The main issues of etiopathogenesis and approaches to the treatment of psoriasis are presented in this article. The most modern current data on the pathogenetic component of psoriasis are reflected. The possibilities of therapeutic measures using targeted therapy have been determined. Psoriasis is a chronic immune-mediated inflammatory disease primarily affecting the skin. The prevalence of psoriasis is 0.4–4%, occurs mainly in adults aged 20 to 60 years, and there is no significant gender difference. Currently, the leading etiopathogenetic role in psoriasis is determined by hereditary immune disorders. Many immune cells involved in the inflammatory process contribute to the pathogenesis and development of psoriasis. The most important in this aspect are Th17, which contribute to the formation of increased amounts of interleukins (IL) 17, which are important in maintaining chronic inflammation associated with the induction and pronounced synergistic effect of other proinflammatory cytokines. Taking into account the available data, it should be noted that IL-17 (mainly IL-17A and IL-17F) are the key cytokines of the pathogenetic component of psoriasis, and human epidermal keratinocytes are the dominant population of skin cells expressing receptors for IL-17. The IL-17 pathway has also been suggested to modulate inflammatory responses linking comorbid systemic diseases to psoriasis. The latest priority research into the etiopathogenesis of psoriasis was the trigger for the creation of a group of fundamentally new genetically engineered biological drugs (GEBPs), and understanding the key role of IL-17 formed the basis for the development of drugs with a targeted effect on this target. The use of a fundamentally new targeted drug – the interleukin IL-17A blocker – netakimab in patients with psoriasis is important and significant in terms of treating cases that are torpid to therapy with cytostatics and phototherapy and achieving prolongation of clinical remission.

1. Кубанов АА, Карамова АЭ, Притуло ОА, Аршинский МИ, Знаменская ЛФ, Чикин ВВ и др. Псориаз: клинические рекомендации. 2023. Режим доступа: https://www.rodv.ru/upload/iblock/a84/q6gxj2hn1mip4m1vaaqg1vyvsy05u11y.pdf.

2. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–212. https://doi.org/10.1111/jdv.13854.

3. Kubanov AA, Bogdanova EV. Epidemiology of psoriasis in the Russian Federation according to the patient registry. Vestnik Dermatologii i Venerologii. 2022;98(2):33–41. (In Russ.) https://doi.org/10.25208/vdv1268.

4. Kubanov АА, Bogdanova EV. Epidemiology of psoriasis among the elderly population and volume of specialized medical care provided to patients with psoriasis in the Russian Federation in 2010–2019. Vestnik Dermatologii i Venerologii. 2020;96(5):7–18. (In Russ.) https://doi.org/10.25208/vdv1171-2020-96-5-07-18.

5. Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019;20(6):1475. https://doi.org/10.3390/ijms20061475.

6. Wu M, Dai C, Zeng F. Cellular Mechanisms of Psoriasis Pathogenesis: A Systemic Review. Clin Cosmet Investig Dermatol. 2023;16:2503–2515. https://doi.org/10.2147/CCID.S420850.

7. Wang MC, Zhang SS, Zheng GX, Huang J, Songyang Z, Zhao X, Lin X. Gainof-function mutation of card14 leads to spontaneous psoriasis-like skin inflammation through enhanced keratinocyte response to IL-17A. Immunity. 2018;49(1):66–79. https://doi.org/10.1016/j.immuni.2018.05.012.

8. Smolyannikova VA, Karamova AÉ, Nefedova MA. Role of IL-17A and neutrophilic granulocytes in the pathogenesis of psoriasis. Arkhiv Patologii. 2020;82(1):30–37. (In Russ.) https://doi.org/10.17116/patol20208201130.

9. Smirnova SV, Smolnikova MV. Immune pathogenesis of psoriasis and psoriatic arthritis. Medical Immunology. 2014;16(2):127–138. (In Russ.) https://doi.org/10.15789/1563-0625-2014-2-127-138.

10. Kostareva OS, Gabdulkhakov AG, Kolyadenko IA, Garber MB, Tishchenko SV. Interleukin-17: Functional and Structural Features, Application as a Therapeutic Target. Biochemistry Moscow. 2019;84(Suppl. 1):193–205. https://doi.org/10.1134/S0006297919140116.

11. Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I et al. Th17 Cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol. 2009;129(9):2175–2183. https://doi.org/10.1038/jid.2009.65.

12. Goncharov AA, Dolgikh O. Immunological and genetic features of pathogenetic association between psoriasis and colonic dysbiosis. Russian Journal of Infection and Immunity. 2021;11(2):237–248. (In Russ.) https://doi.org/10.15789/2220-7619-IAG-1277.

13. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128(5):1207–1211. https://doi.org/10.1038/sj.jid.5701213.

14. Tamarozzi F, Wright HL, Thomas HB, Edwards SW, Taylor MJ. A lack of confirmation with alternative assays questions the validity of IL-17A expression in human neutrophils using immunohistochemistry. Immunol Lett. 2014;162(2):194–198. https://doi.org/10.1016/j.imlet.2014.10.025.

15. Yamanaka K, Yamagiwa A, Akeda T, Kondo M, Kakeda M, Habe K et al. Neutrophils are not the dominant interleukin-17 producer in psoriasis. J Dermatol. 2017;44(7):e170–e171. https://doi.org/10.1111/1346-8138.13807.

16. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397(10281):1301–1315. https://doi.org/10.1016/S0140-6736(20)32549-6.

17. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–390. https://doi.org/10.1016/j.jaad.2016.07.064.

18. Nasonov EL, Denisov LN, Stanislav ML. Interleukin-17 is a new target for anti-cytokine therapy of immune inflammatory rheumatic diseases. Rheumatology Science and Practice. 2013;51(5):545–552. (In Russ.) https://rsp.mediar-press.net/rsp/article/view/1342/1002.

19. Potekaev NN, Zhukova OV, Artemyeva SI. Successful use of Netakimab in the treatment of psoriasis accompanied by the psoriatic onychodystrophy. Meditsinskiy Sovet. 2020;(12):64–70. (In Russ.) https://doi.org/10.21518/2079-701X-2020-12-64-70.

20. Korotaeva TV, Mazurov VI, Lila AM, Gaydukova IZ, Bakulev AL, Samtsov AV et al. Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study. Rheumatology Science and Practice. 2020;58(5):480–488. https://doi.org/10.47360/1995-4484-2020-480-488.

21. Bakulev AL, Samtsov AV, Kubanov AA, Khairutdinov VR, Kokhan MM, Artemyeva AV et al. Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext. Vestnik Dermatologii i Venerologii. 2019;95(3):54–64. (In Russ.) https://doi.org/10.25208/0042-4609-2019-95-3-54-64.